Nkarta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nkarta Therapeutics's estimated annual revenue is currently $23.7M per year.
- Nkarta Therapeutics's estimated revenue per employee is $142,861
- Nkarta Therapeutics's total funding is $125M.
- Nkarta Therapeutics's current valuation is $400M. (January 2022)
Employee Data
- Nkarta Therapeutics has 166 Employees.
- Nkarta Therapeutics grew their employee count by 11% last year.
Nkarta Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Nkarta Therapeutics?
Nkarta Therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. Nkarta was founded on the proprietary, robust and well characterized natural killer (NK) cell expansion technology pioneered by Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. Founded in 2015, the company?s investors include SR One, NEA and Novo Ventures. For more information, please visit the company?s website at www.nkartatx.com.
keywords:N/A
$125M
Total Funding
166
Number of Employees
$23.7M
Revenue (est)
11%
Employee Growth %
$400M
Valuation
N/A
Accelerator
Nkarta Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Legal Officer | Reveal Email/Phone |
2 | SVP Finance | Reveal Email/Phone |
3 | Director Clinical Operations | Reveal Email/Phone |
4 | Senior Scientist | Reveal Email/Phone |
5 | Associate Scientist | Reveal Email/Phone |
6 | Principal Scientist | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | SVP, Public Affairs and Investor Relations | Reveal Email/Phone |
9 | Supply Chain Supervisor | Reveal Email/Phone |
10 | Manager, Manufacturing | Reveal Email/Phone |
Nkarta Therapeutics News
Nkarta Offices Nkarta has released early data for its two leading engineered natural killer cell programs. (nkarta therapeutics ).
In the battle of Car-NK therapy companies Nkarta today looks to have at least matched Fate Therapeutics. The big difference for investors will...
Nkarta is one of the leading companies in the push to develop immunotherapies based on natural killer, or NK cells, part of the body's first...
Biopharmaceutical company Nkarta Therapeutics announced it has raised $114 million in Series B funding Nkarta Therapeutics — a biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer — recently announced it closed an oversubscribed $114 million Series ...
Nkarta Therapeutics, a South San Francisco, Calif.–based biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, closed a $114m Series B financing. The round was led by new investor Samsara BioCapital, with participation from new investors Amgen Ventu ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27.4M | 172 | N/A | N/A |
#2 | $33.7M | 174 | -8% | $278.1M |
#3 | $76.7M | 176 | -32% | $420.4M |
#4 | $59.4M | 177 | -2% | N/A |
#5 | $23.4M | 178 | 11% | $319.7M |